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Abstract Neoadjuvant treatment in non-metastatic pan-
creatic cancer (PaC) has the theoretical advantages of
downstaging the tumor, sterilizing any present systemic
undetectable disease, selecting patients for surgery and
administering therapy to each patient. The aim of this
systematic review is to analyze the state of the art on
neoadjuvant protocols for non-metastatic PaC. A literature
search over the last 10 years was conducted, and papers
had to be focused on resectable, borderline
resectable (BLR) or locally advanced (LA) histo- or cyto-
logically proven PaC; to be prospective studies or
prospectively collected databases; to report percentage of
protocol achievement and survival data at least in an
intention-to-treat (ITT) analysis. Twelve studies were eli-
gible for systematic review. Studies included a total of 624
patients: 248 resectable, 268 BLR, 71 LA and 37 non-
specified. All studies were included for meta-analysis. ITT
overall survival (OS) was 16.7 months (95% CI
15.16–18.26 months); for resected patients OS was 22.78
months (95% CI 20.42–25.16), and for eventually non-re-
sected patients it was 9.89 months (95% CI 8.84–10.96).
Neoadjuvant approaches for resectable, BLR and LA PaC
are spreading. Outcomes tend to be better outside an RCT
context, but strong evidences are lacking. Actually such
treatments should be performed only in a randomized
clinical trial setting.
Keywords Pancreatic cancer  Neoadjuvant therapy 
Survival  Borderline  Resectable  Surgery
Introduction
Pancreatic cancer (PaC) is one of the most challenging
global health burdens that physicians are facing nowadays.
Its 5-year survival in non-metastatic stages ranges between
3 and 14% [1], while surgery remains the only chance for
long survivors. Currently, the standard of care advocates a
surgery-first approach in resectable situations followed by
adjuvant treatment, but neoadjuvant approaches are
spreading either in resectable and in borderline
resectable (BLR) and locally advanced (LA) patients.
Whether this attitude provides to the patient a survival
advantage is a widespread belief but not a matter of fact.
The National Comprehensive National Network states that
there is limited evidence to recommend specific neoadju-
vants regimens off-study [2]. While the only choice in LA
PaC is a loco-regional chemoradiation or systemic
chemotherapy and subsequent revaluation, for
resectable and BLR we must choose between a surgery-first
approach and a neoadjuvant treatment. Over 40% of patients
who have clinically a resectable disease are found unre-
sectable at surgery, even though this percentage drops to
20% if a diagnostic laparoscopy is added to the preoperative
diagnostic panel [3], and one out of five patients are even-
tually misdiagnosed as resectable or BLR while having a
LA disease. Moreover, 27% of BLR patients will require a
vascular resection in order to achieve their pancreatectomy
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[4], but histologic invasion of resected vessel will be con-
firmed only in 56.7% of specimens [5]. Finally, up to 28% of
successfully resected patients will not undergo adjuvant
therapies because of surgical morbidity, poor performance
status, refusal or early recurrence [5]. A preoperative
treatment has the theoretical advantages of delivering sys-
temic therapy to all patients in a healthy tumor bed and
identifying tumors with an aggressive biology and thus
patients who would not benefit from surgery.
The aim of this systematic review is to analyze the bulk
of knowledge on neoadjuvant protocols for non-metastatic
pancreatic cancer and derive a meta-analysis of its results.
Materials and methods
Following the criteria of the PRISMA statement, a com-
prehensive PubMed, Embase and Cochrane library search
was conducted looking for studies focusing on neoadjuvant
therapies in non-metastatic pancreatic cancer. The key-
words used were ‘pancreatic cancer or carcinoma’ and
‘neoadjuvant therapy or treatment.’ The research was
restricted to the last 10 years (June 2006–June 2016) and to
English language articles dealing with human patients.
Papers had to be focused on resectable, borderline
resectable or locally advanced histo- or cytologically pro-
ven pancreatic adenocarcinoma; to be prospective studies
or prospectively collected databases; to report the per-
centage of protocol achievement and survival data at least
in an intention-to-treat (ITT) analysis. Exclusion criteria
were retrospective studies, RCT papers, periampullary
cancers and missing outcomes data. Data extraction was
carried out by two independent investigators. Primary
outcome was ITT overall survival (OS), and secondary
outcomes were protocol achievement, R0 resection rate,
specific resectable, resected and unresected OS.
Pooled survival times and proportions were computed
by means of meta-analyses. Each separate meta-analysis
conducted was strictly under heterogeneity among studies,
by means of a hierarchical Bayesian model. Homogeneity
was not assessed due to the limited number of studies, and
instead we worked under heterogeneity through hierarchi-
cal models [6]. Median survival times and logistic trans-
forms of proportions were assumed to be normally
distributed. Each study summary was assumed to arise
from a Gaussian centered on a study-specific effect and
with variance corresponding to the square of its estimated
standard error, inflated by 25% in order to guarantee con-
servative statements. The study-specific summary was
assumed to be Gaussian, centered on an unknown pooled
measure, which was the main object of interest. Summaries
for proportions were then back-transformed appropriately.
As per guidelines with limited number of studies involved,
informative priors were used. For the variance of the
pooled measures, we assumed an inverse Gamma centered
on an estimator obtained with a moment-based approach
(inflated by 25% for similar reasons as above). Potential
publication bias was estimated using Egger’s linear
regression tests, which were never significant.
The systematic review’s protocol was regularly regis-
tered at www.researchregistry.com with the unique iden-
tifying number of review registry 102.
Results
Papers selection and systematic review
The extensive literature search led to the identification of
612 English papers over the past 10 years focusing on
neoadjuvant treatment for resectable, BLR and LA PaC, of
which 12 papers eligible for the systematic review (Fig. 1)
[7–18]. Papers were published over a 8-year period,
between 2008 and 2015.
Studies characteristics
Studies included between 15 and 246 patients, with a total
of 624 patients: 248 resectable, 268 borderline resectable,
71 locally advanced and 37 non-specified (Table 1). Four
papers were restricted to resectable patients [9, 12, 17, 18],
one to LA patients [8] and one to BLR patients [10].
Treatment plans included: six studies offer a systemic
chemotherapy [9, 11, 13, 15, 16, 18], three a loco-regional
chemoradiation regimen [8, 12, 17] and three a combina-
tion of the two [7, 10, 14]. Gemcitabine has been the most
widely used antineoplastic agent (Table 1). All studies
reported ITT-OS. One study didn’t report OS neither for
eventually resected patients nor for post-neoadjuvant
unresectable patients [12]. Two studies didn’t report OS for
post-neoadjuvant unresectable patients [9, 18]. One study
didn’t report resection margins [8].
Definition of resectability
The definition of resectability varies among studies
(Table 2). The most cited classification [10, 14–16] is
Callery’s one from the expert consensus statement spon-
sored by the American Hepato-Pancreato-Biliary Associa-
tion and others [19]. Five studies used their own definitions
[9, 11, 12, 17, 18].
Protocol achievement
The ITT population includes 624 patients submitted to
neoadjuvant therapy. A total of 395 patients eventually
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underwent surgical resection with curative intent. Protocol
achievement in terms of completion of the proposed
neoadjuvant treatment followed by pancreatectomy ranged
26.7–89.28% (Table 1), and at the meta-analysis it was
65% (95% CI 62–67%) with a regression test of p = 0.366
(Fig. 2).
Resection margins
One paper failed to report data on resection margins [8]. Of
the 395 resected patients, 391 resection margins were
specified: 355 R0, 35 R1 and 1 R2. R0 rate ranged
69.2–100% (Table 1), and at the meta-analysis it was 94%
(95% CI 93–95%) with a regression test of p = 0.0913
(Fig. 3).
Survival
Intention-to-treat overall survival ranged 13.5–27.2 months
(Table 1), and at the meta-analysis ITT-OS was
16.7 months (95% CI 15.16–18.26 months) with a regres-
sion test of p = 0.1087 (Fig. 4).
OS of eventually resected patients ranged
15–36.5 months (Table 1), and at the meta-analysis resected
OS was 22.78 months (95% CI 20.42–25.16 months) with a
regression test of p = 0.0582 (Fig. 5).
Finally OS of post-neoadjuvant treatment unre-
sectable patients ranged 8.6–13.2 months (Table 1), and at
the meta-analysis unresectable OS was 9.89 months (95%
CI 8.84–10.96 months) with a regression test of p = 0.379
(Fig. 6).
We conducted a subgroup analysis of studies dealing
with resectable only patients [9, 12, 17, 18], and this
analysis takes into account a total of 123 patients: ITT-OS
in this setting ranged 15.5–27.2 months (Table 1), and at
the meta-analysis resectable ITT-OS was 18.16 months
(95% CI 14.08–22.45 months) with a regression test of
p = 0.5293 (Fig. 7).
Among those studies restricted to resectable patients,
three reported OS of eventually resected patients
[9, 17, 18]: 69 out of 97 clinically resectable patients have
been resected. The OS of eventually resected patients in
this setting ranged 19.1–32 months, and at the meta-anal-
ysis it was 20.87 months (95% CI 17.97–23.82 months)
with a regression test of p = 0.5205 (Fig. 8).
Discussion
RCTs focusing on neoadjuvant therapies are lacking, and
the existing three trials conducted on resectable PaC report
a protocol achievement of 18.18–70% and an ITT survival
of 9.9–19.4 months [23]: Palmer et al. [24] report a
resection rate of 54% after neoadjuvant treatment, of which
75% R0 resections; Golcher reports a non-statistically
significant difference of resection rate in the neoadjuvant
group (57.57%) versus the upfront surgery group (69.69%),
and there is to say that this study has been terminated
Fig. 1 Studies’ selection flow chart
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Table 2 Definitions of resectable, borderline resectable and locally advanced pancreatic cancer among studies
References Resectable Borderline resectable Locally advanced Reference
classification
Miura
et al. [7]
No CA/SMA/HA abutment; SMV,
PV or SMV-PV confluence
narrowing\50%
SMA or CA abutment\180;
abutment or short encasement of
HA; SMV, PV or SMV-PV
confluence narrowing[50% or
short segment occlusion (allowing
for reconstruction); suspicion (not
diagnosis) of metastatic disease
SMA/CA encasement
[180; occlusion of SMV,
PV or SMV-PV
confluence not allowing
for reconstruction
Appel et al. [20]
Kapoor
et al. [8]
– – Encasement/involvement of
SMA/CA
Tempero et al. [21]
O’Reilly
et al. [9]
Clear fat plane around CA and SMA,
patent SMV/PV, no SMV
encasement or PV involvement, no
HA or SMA encasement, no extra-
regional nodal disease
– – –
Rose et al.
[10]
No evidence of SMV or PV
abutment, distortion, tumor
thrombus or venous encasement
and clear fat planes around CA, HA
and SMAa
Involvement of SMV/PV allowing
for reconstruction, GDA or HA
involvement/encasement w/o
extension to CA or abutment of
SMA\ 180a
Major venous thrombosis of
PV/SMV, encasement of
SMA, CA or proximal
HAa
Callery et al. [19]a
Motoi
et al.
[11]
– Encasement of PV/SMV and/or
abutment of HA or SMA within
180
– –
Shinoto
et al.
[12]
No involvement of HA, CA or SMA – – –
Lee et al.
[13]
Clear tissue plane around SMA, CA,
HA and SMV/PV
SMA or CA abutment or GDA
encasement up to origin of HA or
SMV short segment occlusion
SMA or CA or HA
encasement or SMV/PV
occlusion
NCCN Pancreatic
Adenocarcinoma
Guidelines
version 1.2008
[22]
Pipas et al.
[14]
No evidence of SMV or PV
abutment, distortion, tumor
thrombus or venous encasement
and clear fat planes around CA, HA
and SMA
Involvement of SMV/PV allowing
for reconstruction, GDA or HA
involvement/encasement w/o
extension to CA or abutment of
SMA\ 180
Major venous thrombosis of
PV/SMV, encasement of
SMA, CA or proximal HA
Callery et al. [19]
Sahora
et al.
[15]
No evidence of SMV or PV
abutment, distortion, tumor
thrombus or venous encasement
and clear fat planes around CA, HA
and SMA
Involvement of SMV/PV allowing
for reconstruction, GDA or HA
involvement/encasement w/o
extension to CA or abutment of
SMA\ 180
Major venous thrombosis of
PV/SMV, encasement of
SMA, CA or proximal HA
Callery et al. [19]
Sahora
et al.
[16]
No evidence of SMV or PV
abutment, distortion, tumor
thrombus or venous encasement
and clear fat planes around CA, HA
and SMA
Involvement of SMV/PV allowing
for reconstruction, GDA or HA
involvement/encasement w/o
extension to CA or abutment of
SMA\ 180
Major venous thrombosis of
PV/SMV, encasement of
SMA, CA or proximal HA
Callery et al. [19]
Turrini
et al.
[17]
Involvement of SMV/PV\ 180, no
occlusion of SMV or PV
confluence, no extension to SMA or
CA, no extrahepatic disease
– – –
Heinrich
et al.
[18]
cT1, cT2, cT3s. AJCC classification
7th ed.
– – –
PI principal investigator, SMV superior mesenteric vein, PV portal vein, HA hepatic artery, CA celiac axis, SMA superior mesenteric artery, GDA
gastroduodenal artery, w/o without, AJCC American Joint Committee on Cancer
a Criteria specified at restaging
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because of the poor recruitment rate and did not reach the
necessary sample size [25]; Landry reported a resection
rate of 23.8% after neoadjuvant treatment of locally
advanced potentially resectable PaC, of which 40% R0
resections [26].
Selected retrospective single-institution experiences
over resectable BLR and LA PaC report OS up to
43.4 months in resected patients following chemotherapy
or chemoradiation [27]. According to Mellon and col-
leagues, patients with BLR or LA PaC and sufficient
response to neoadjuvant multi-agent chemotherapy and
stereotactic body radiation therapy have similar or
improved perioperative and long-term survival outcomes
compared to upfront resection patients [28]. In this paper
neoadjuvant therapy in BLR–LA patients was compared to
upfront resected patients. In the ITT analysis the neoad-
juvant group had a worse survival (17.0 vs 22.1 months,
p = 0.029); such comparison has little significance
because in the first group 61.6% of patients was eventually
unresectable while in the upfront surgery group accounted
only resected patients. Moreover, patients of the upfront
surgery group who failed to receive adjuvant treatment
(20.3%) were excluded from analysis. Indeed, there was no
significant difference in survival between the two groups
among only resected patients (33.5 vs 23.1 months,
p = 0.057) [28].
In this meta-analysis including resectable, BLR and LA
PaC, we observe a protocol achievement of 65% with an
R0 rate of 94% and an ITT survival of 16.7 months. The
subgroup analysis restricted to resectable patients shows an
ITT survival of 18.16 months, and among them eventually
resected patients have OS of 20.87 months. Overall, two
patients out of three have been treated as intended/planned.
Surprisingly, survival of patients eventually resected
among resectable ones wasn’t better than overall survival
of resected patients (20.87 vs 22.78 months). This may be
explained by the fact that preoperative staging is far from
being accurate. As already said, to the best of clinical
practice, one out of five patients is wrongly taken to the OR
with a curative intent while having a LA PaC.
In Miura’ study, while in the ITT analysis clinically
BLR disease was an independent poor prognostic indicator,
among resected patients OS did not differ between preop-
eratively classified resectable and BLR patients [7]. This
confirms that once resected, preoperative staging doesn’t
influence patients’ outcomes.
Histologic confirmation of the disease is mandatory
before administering neoadjuvant treatment even though
up to 16% of preoperatively cyto/histologically diagnosed
pancreatic cancers eventually receive a final pathological
diagnosis other than PaC [18], thus receiving a useless
Fig. 2 Forest plot protocol achievement
Fig. 3 Forest plot R0
Fig. 4 Forest plot ITT-OS
Fig. 5 Forest plot resected OS
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neoadjuvant treatment. In Golcher’ study pathological
diagnosis of PaC at biopsy has been rejected in 4.5% of
resected patients (because of the finding of a distal chole-
dochal adenocarcinoma and a duodenal adenocarcinoma)
[25].
The use of different classifications over time makes
extremely difficult the interpretation of the literature.
NCCN guidelines endorse the consensus statement of the
Society of Abdominal Radiology and the American Pan-
creatic Association [29] to define resectable, borderline
resectable and locally advanced pancreatic cancer. The
unanimous use of this classification might clarify the
impact of neoadjuvant treatments on the survival of those
patients.
Outcomes tend to be better outside an RCT context; the
literature is influencing our conduct, but strong evidences
come only from well-designed randomized trials. More
effort should be addressed toward the comprehension of the
potential benefit that patients could gain from neoadjuvant
approach.
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